Latest Dextroamphetamine Stories

PHILADELPHIA, May 17, 2013 /PRNewswire/ -- Research explores data on treatments for psychiatric disorders; health economics and outcomes research also to be presented Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announces that it will present scientific data in 7 poster presentations at the American Psychiatric Association (APA) 166th Annual Meeting in San Francisco, May 18-22. The data being presented...

CANTON, Mass., May 8, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the presentation of a scientific poster titled "Oxycodone DETERx®, an Extended-release, Abuse-deterrent Formulation for the Management of Chronic Pain," at the American Pain Society's 32(nd) Annual Scientific Meeting, held in New Orleans, Louisiana from May 8(th) to May 10(th). This...

Becomes the first stimulant medication approved for maintenance treatment in patients ages 6 and above with ADHD PHILADELPHIA, May 1, 2013 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse(R) (lisdexamfetamine dimesylate) Capsules, (CII) as a maintenance treatment in children and adolescents with...

-Oxycodone DETERx® resistant to tampering via chewing and crushing CANTON, Mass., April 17, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced top-line results from its recently completed Phase I clinical trial for Oxycodone DETERx®, its extended-release, abuse-deterrent, multi-particulate product in a capsule form. The product utilizes Collegium's DETERx®...

Company to explore commercial partnerships for its lead product, Oxycodone DETERx® (COL-003), an abuse-deterrent, extended-release product for chronic pain CANTON, Mass., April 3, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, has hired Douglas Carlson in the newly-created position of Vice President of Business Development. Doug previously held the position of Senior...

FDA, peer-reviewed research support effectiveness of Vyvanse® as an ADHD treatment MARGATE CITY, N.J., March 12, 2013 /PRNewswire/ -- MDC announces the availability of a Vyvanse coupon through its website, redeemable towards prescriptions of Vyvanse from pharmacies. The coupon can be accessed from the bottom portion of http://medicationdiscountcard.com/drug/vyvanse-coupon/ to save up to 50% on your copay. Vyvanse (lisdexamfetamine dimesylate) is an FDA-approved medication used for...

NYON, Switzerland, December 18, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) today announces a positive outcome from the European Decentralised Procedure (DCP) for Elvanse(R) (to be known as Tyvense(R) in Ireland). Elvanse is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged 6 years of age and over when response to previous methylphenidate treatment is considered clinically inadequate.[1]...

PHILADELPHIA, Sept. 12, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the US Food and Drug Administration (FDA) has accepted the filing for review of a supplemental New Drug Application (sNDA) for Vyvanse(®) (lisdexamfetamine dimesylate) Capsules, (CII). Shire is seeking approval of Vyvanse as a maintenance treatment in children and adolescents ages 6 to 17 years with Attention-Deficit/Hyperactivity Disorder (ADHD). There are currently no...

MORRISTOWN, N.J., June 25, 2012 /PRNewswire/ -- Actavis Group, an international generic pharmaceuticals company, today announced that it has received approval from the US Food & Drug Administration to market Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended-Release Capsules CII, (hereafter referred to as Mixed Amphetamine Salts ER Capsules), in all available strengths: 5mg, 10mg, 15mg, 20mg, 25mg, and...

Misuse of prescription drugs seen as 'more necessary' for success, study finds In the eyes of young college men, it's more unethical to use steroids to get an edge in sports than it is to use prescription stimulants to enhance one's grades, according to new research published by the American Psychological Association. And students who had themselves used stimulants without a prescription were more inclined to see such drug use as acceptable, according to the findings, which were...